SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol. 2000; 78: 97105.
  • 2
    Beral V, Hermon C, Munoz N, Devesa SS. Cervical cancer. Cancer Surv. 1994; 19–20: 265285.
  • 3
    Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer. 1998; 75: 536545.
  • 4
    Zaino RJ. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 2002; 21: 314326.
  • 5
    Schwartz SM, Weiss NS. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol. 1986; 124: 10451047.
  • 6
    Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet. 2001; 357: 14901493.
  • 7
    Alfsen GC, Thoresen SO, Kristensen GB, Skovlund E, Abeler VM. Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990. Cancer. 2000; 89: 12911299.
  • 8
    Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ. 2001; 164: 11511152.
  • 9
    Sigurdsson K. Quality assurance in cervical cancer screening: the Icelandic experience 1964–1993. Eur J Cancer. 1995; 31A: 728734.
  • 10
    Herbert A, Singh N, Smith JA. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire. Cytopathology. 2001; 12: 2636.
  • 11
    Romero AA, Key C, Smith H. Changing trends in the incidence rates for adenocarcinoma and squamous cell carcinoma by age, race, and stage. A 25-year population-based study. Gynecol Oncol. 2001; 80: 295296.
  • 12
    Devesa SS, Young JL Jr., Brinton LA, Fraumeni JF Jr. Recent trends in cervix uteri cancer. Cancer. 1989; 64: 21842190.
  • 13
    Peters RK, Chao A, Mack TM, Thomas D, Bernstein L, Henderson BE. Increased frequency of adenocarcinoma of the uterine cervix in young women in Los Angeles County. J Natl Cancer Inst. 1986; 76: 423428.
  • 14
    Zheng T, Holford TR, Ma Z, et al. The continuing increase in adenocarcinoma of the uterine cervix: a birth cohort phenomenon. Int J Epidemiol. 1996; 25: 252258.
  • 15
    Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of cervix uteri. Obstet Gynecol. 1995; 85: 10171021.
  • 16
    Ries LAG, Eisner MP Kosary CL. et al. SEER cancer statistics review, 1973–1998. Bethesda, MD: National Cancer Institute, 2001. Available from URL: http://seer.cancer.gov/publications/CSR1973_1998/2001 [accessed September 2003].
  • 17
    Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology, and End Results Program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999; 8: 11171121.
  • 18
    Plaxe SC, Saltzstein SL. Estimation of the duration of the preclinical phase of cervical adenocarcinoma suggests that there is ample opportunity for screening. Gynecol Oncol. 1999; 75: 5561.
  • 19
    Berg JW. Morphologic classification of human cancer. In: SchottenfeldD, FraumeniJFJ, editors. Cancer epidemiology and prevention, 2nd edition. New York: Oxford University Press, 1996: 2844.
  • 20
    World Health Organization. International classification of diseases for oncology. Geneva: World Health Organization, 1990.
  • 21
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat data base: incidence—SEER 9 regs public-use, November, 2001 sub (1973–1999). Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, 2003. Available from URL: www.seer.cancer.gov [accessed September 2003].
  • 22
    Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 5.0.18. Bethesda, MD: National Cancer Institute, 2003. Available from URL: www.seer.cancer.gov/seerstat] [accessed September 2003].
  • 23
    Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol. 1995; 141: 300304.
  • 24
    Young JL Jr., Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER summary staging manual—2000: codes and coding instructions. National Institutes of Health pub. no. 01-4969. Bethesda, MD: National Cancer Institute, 2001.
  • 25
    Hewitt M, Devesa S, Breen N. Papanicolaou test use among reproductive-age women at high risk for cervical cancer: analyses of the 1995 National Survey of Family Growth. Am J Public Health. 2002; 92: 666669.
  • 26
    Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 15281540.
  • 27
    Schairer C, Brinton LA, Devesa SS, Ziegler RG, Fraumeni JF Jr. Racial differences in the risk of invasive squamous-cell cervical cancer. Cancer Causes Control. 1991; 2: 283290.
  • 28
    Devesa SS. Descriptive epidemiology of cancer of the uterine cervix. Obstet Gynecol. 1984; 63: 605612.
  • 29
    [No authors listed.] The Bethesda System for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop, April 29–30, 1991. Acta Cytol. 1993; 37: 115124.
  • 30
    Henson RM, Wyatt SW, Lee NC. The National Breast and Cervical Cancer Early Detection Program: a comprehensive public health response to two major health issues for women. J Public Health Manag Pract. 1996; 2: 3647.
  • 31
    Reynolds T. States begin CDC-sponsored breast and cervical cancer screening. J Natl Cancer Inst. 1992; 84: 79.
  • 32
    Crum CP. Binary (Bethesda) system for cervical precursor lesions: a histologic perspective. Diagn Cytopathol. 1995; 13: 379385.
  • 33
    Crum CP, McLachlin CM. Cervical intraepithelial neoplasia. J Cell Biochem. 1995; 23(Suppl): 7179.
  • 34
    Mahon SM. Prevention and early detection of cancer in women. Semin Oncol Nurs. 1995; 11: 88102.
  • 35
    Beral V, Booth M. Predictions of cervical cancer incidence and mortality in England and Wales. Lancet. 1986; 1: 495.
  • 36
    Allen KA, Zaleski S, Cohen MB. Review of negative Papanicolaou tests. Is the retrospective 5-year review necessary? Am J Clin Pathol. 1994; 101: 1921.
  • 37
    Helfand M, O'Connor GT, Zimmer-Gembeck M, Beck JR. Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) on the incidence of invasive cervical cancer. Med Care. 1992; 30: 10671082.
  • 38
    [No authors listed.] Results from the National Breast and Cervical Cancer Early Detection Program, October 31, 1991–September 30, 1993. MMWR Morb Mortal Wkly Rep. 1994; 43: 530534.
  • 39
    From the Centers for Disease Control and Prevention. Update: National Breast and Cervical Cancer Early Detection Program, 1992–1993. JAMA. 1993; 270: 17931794.
  • 40
    [No authors listed.] Update: National Breast and Cervical Cancer Early Detection Program, July 1991–July 1992. MMWR Morb Mortal Wkly Rep. 1992; 41: 739743.
  • 41
    Murdoch JB, Grimshaw RN, Morgan PR, Monaghan JM. The impact of loop diathermy on management of early invasive cervical cancer. Int J Gynecol Cancer. 1992; 2: 129133.
  • 42
    Taylor PT Jr., Andersen WA, Barber SR, Covell JL, Smith EB, Underwood PB Jr. The screening Papanicolaou smear: contribution of the endocervical brush. Obstet Gynecol. 1987; 70: 734738.
  • 43
    Wilbur DC. Endocervical glandular atypia: a “new” problem for the cytologist. Diagn Cytopathol. 1995; 13: 463469.
  • 44
    Smith HO, Padilla LA. Adenocarcinoma in situ of the cervix: sensitivity of detection by cervical smear: will cytologic screening for adenocarcinoma in situ reduce incidence rates for adenocarcinoma? Cancer. 2002; 96: 319322.
  • 45
    Kjaer SK, Brinton LA. Adenocarcinomas of the uterine cervix: the epidemiology of an increasing problem. Epidemiol Rev. 1993; 15: 486498.
  • 46
    Lacey JV Jr., Brinton LA, Abbas FM, et al. Oral contraceptives as risk factors for cervical adenocarcinomas and squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev. 1999; 8: 10791085.
  • 47
    Altekruse SF, Lacey JV Jr., Brinton LA, et al. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol. 2003; 188: 657663.
  • 48
    Thomas DB, Ray RM. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. The World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol. 1996; 144: 281289.
  • 49
    Ursin G, Peters RK, Henderson BE, d'Ablaing G III, Monroe KR, Pike MC. Oral contraceptive use and adenocarcinoma of cervix. Lancet. 1994; 344: 13901394.
  • 50
    Lacey JV Jr., Swanson CA, Brinton LA, et al. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003; 98: 814821.
  • 51
    Madeleine MM, Daling JR, Schwartz SM, et al. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev. 2001; 10: 171177.
  • 52
    Abma JC, Chandra A, Mosher WD, Peterson LS, Piccinino LJ. Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Vital Health Stat. 23 1997; 1114.
  • 53
    Kumanyika S. Obesity in black women. Epidemiol Rev. 1987; 9: 3150.
  • 54
    Okosun IS, Choi ST, Boltri JM, et al. Trends of abdominal adiposity in white, black, and Mexican-American adults, 1988 to 2000. Obes Res. 2003; 11: 10101017.
  • 55
    Hiatt RA, Klabunde C, Breen N, Swan J, Ballard-Barbash R. Cancer screening practices from National Health Interview Surveys: past, present, and future. J Natl Cancer Inst. 2002; 94: 18371846.
  • 56
    Coughlin SS, Thompson TD, Seeff L, Richards T, Stallings F. Breast, cervical, and colorectal carcinoma screening in a demographically defined region of the southern U.S. Cancer. 2002; 95: 22112222.
  • 57
    Saraiya M, Lee NC, Blackman D, Smith MJ, Morrow B, McKenna MA. Self-reported Papanicolaou smears and hysterectomies among women in the United States. Obstet Gynecol. 2001; 98: 269278.
  • 58
    Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention. Behavioral risk factor surveillance system online prevalence data, 1995–2002. Atlanta: Centers for Disease Control and Prevention, 2003.
  • 59
    Schoolland M, Segal A, Allpress S, Miranda A, Frost FA, Sterrett GF. Adenocarcinoma in situ of the cervix. Cancer. 2002; 96: 330337.
  • 60
    Kinney W, Sawaya GF, Sung HY, Kearney KA, Miller M, Hiatt RA. Stage at diagnosis and mortality in patients with adenocarcinoma and adenosquamous carcinoma of the uterine cervix diagnosed as a consequence of cytologic screening. Acta Cytol. 2003; 47: 167171.